Who Supplies Aspirin to India from SOUTH AFRICA

Importing finished pharmaceutical formulations containing Aspirin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before applying for registration or import. Applications for registration and import should be submitted to the Licensing Authority, the Drugs Controller General (India), at the CDSCO office.

Imported pharmaceutical formulations containing Aspirin must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided. Port inspections by customs drug inspectors are conducted to ensure compliance with these standards.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and South Africa have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP). These agreements aim to streamline the import process and enhance trade relations.

India imports finished Aspirin formulations to meet domestic demand for patented and branded products, as well as specific dosage forms not produced locally. The domestic pharmaceutical industry has the capacity to manufacture standard Aspirin formulations; however, imports are necessary to fulfill niche market requirements. The market size for Aspirin formulations in India is substantial, with a total export market of $37.8 million across 327 exporters to 121 countries.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations containing Aspirin (HS Code 30049062) is 10%. Additional taxes include the Social Welfare Surcharge (SWS) at 10% and the Integrated Goods and Services Tax (IGST) at 12%. These duties are standard for imports from all countries, including South Africa. Exemptions or concessional rates may apply under specific Free Trade Agreements (FTAs) or bilateral agreements. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.

India sources finished Aspirin formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality products. South African manufacturers offer unique formulations not produced domestically, providing a competitive advantage. Other suppliers include China, Germany, and the United States; however, South Africa's share in the Indian market is notable due to these factors.

India imports finished Aspirin formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality products not produced domestically. South African manufacturers offer unique formulations that cater to specific market needs in India, providing a competitive advantage.

Compared to other origins such as China, the European Union, and the United States, South Africa offers competitive pricing, high-quality products, and compliance with international regulatory standards. The unique formulations and specialized dosage forms available from South African manufacturers provide a distinct advantage in the Indian market.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While past shortages have been minimal, it is advisable for importers to monitor these risks and develop contingency plans.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts.
5. 5Supplier Qualification: Conduct thorough due diligence to assess supplier reliability, quality standards, and compliance with regulatory requirements.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the drug and manufacturing site with the CDSCO.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): Obtain an NOC from the CDSCO if required.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049062 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Issued by the relevant authority.
4. 4Drug Master File (DMF): Providing detailed information on the manufacturing process.